Corpus Intelligence IC Memo — TEXAS HEALTH KAUFMAN 2026-04-26 13:36 UTC
IC Memo — TEXAS HEALTH KAUFMAN
Investment Committee Memorandum | TX | 42 beds | Grade C | EBITDA uplift $3.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TEXAS HEALTH KAUFMAN

CCN 450292 | KAUFMAN, TX | 42 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TEXAS HEALTH KAUFMAN is a 42-bed suburban community hospital in KAUFMAN, TX with $44.8M in net patient revenue and a 12.6% operating margin. The hospital serves a payer mix of 26.4% Medicare, 0.2% Medicaid, and 73.5% commercial.

Thesis: Turnaround. Our ML models identify $3.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 12.6% to 20.0% (+736bps).

Net Revenue HCRIS$44.8M
Current EBITDA COMPUTED$5.7M
Operating Margin COMPUTED12.6%
Occupancy HCRIS17.6%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS22.8%
Distress Probability ML53.8%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
283
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 12.6% places it above the state median. Among 283 size-comparable peers (21-84 beds), the median margin is -2.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (21-84), prioritizing same-state peers. 283 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TEXAS HEALTH KAUFMAN (Target)TX42$44.8M12.6%
DECATUR COMMUNITY HOSPITALTX81$361.0M-15.5%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CHILDRENS MEDICAL CENTER OF PLTX72$336.7M20.9%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
BAYLOR HEART AND VASCULAR HOSPTX53$255.0M30.0%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
LAKE GRANBURY MEDICAL CENTERTX53$181.6M38.5%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$942K+210bp18mo
Cost to Collect4.5%2.5%$897K+200bp12mo
Denial Rate Reduction12.0%6.5%$888K+198bp12mo
A/R Days Reduction5200.0%3800.0%$546K+122bp9mo
Clean Claim Rate88.0%96.0%$29K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$942K
Cost to Collect
$897K
Denial Rate Reduction
$888K
A/R Days Reduction
$546K
Clean Claim Rate
$29K
Total EBITDA Uplift$3.3M
Current EBITDA$5.7M
+ RCM Uplift+$3.3M
Pro Forma EBITDA$9.0M
Current Margin12.6%
Pro Forma Margin20.0%
WC Released (1x)$1.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$8.7M$70.4M8.07x51.8%
Base (11x exit)10.0x11.0x$8.7M$80.3M9.20x55.9%
Bull Case9.0x11.0x$7.8M$94.0M11.98x64.3%
Bull (12x exit)9.0x12.0x$7.8M$104.8M13.36x67.9%
Bear Case11.0x10.0x$9.6M$51.1M5.32x39.7%
Bear (11x exit)11.0x11.0x$9.6M$59.3M6.18x44.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 17.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 283 hospitals with 21-84 beds
  • Same-state prioritization (n=284)
  • Comp margins: P25=-22.7% / P50=-2.6% / P75=10.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.